Submit your Manuscript
  • info@jjgastro.com
  • ISSN 3065-5498
Submit your Manuscript

Volume 3, Issue 2

Perioperative chemotherapy versus upfront surgery with adjuvant chemotherapy in gastric and esophagogastric junction adenocarcinoma: A retrospective trial

www.doi.org/10.52768/jjgastro/1132

Gastric cancer represents a common cause of cancer death worldwide. Adenocarcinoma accounts for more than 95% of all gastric malignancies. Multimodal approaches in the treatment of localized gastric cancer have changed the natural history of the disease. Compared with surgery alone, several therapeutic approaches including perioperative chemotherapy or adjuvant chemotherapy improve survival.

Research progress of miRNA-326 in malignant tumors Abstract

www.doi.org/10.52768/jjgastro/1133

MicroRNAs (miRNAs) are endogenous mediators of RNA interference and have key roles in the regulation of cell and tissue gene expression under a healthy, inflamed, stimulated, carcinogenic, or pathological states. The imbalance between miRNA and genes can cause a series of diseases, including malignancies. The role of miR‐326 as a tumor suppressor miRNA in much human cancer confirmed.

Ulcerative colitis and autoimmune hemolytic anemia in adult male patient: A rare case report

www.doi.org/10.52768/jjgastro/1134

Autoimmune Haemolytic Anemia (AIHA) as a manifestation of Ulcerative Colitis (UC) is a rare occurrence. This case report describes a 21-year-old male patient diagnosed with UC who was treated with medication, but 11 months later developed Coombs-positive AIHA. Although AIHA in UC patients is more commonly observed in females with pancolitis, the exact mechanism behind this phenomenon remains unclear.

Atezolizumab plus bevacizumab followed by lenvatinib in a case of unresectable hepatocellular carcinoma with Vp4 and child-pugh B

www.doi.org/10.52768/jjgastro/1135

Hepatocellular Carcinoma (HCC) with Portal Vein Tumor Thrombus (PVTT) is a highly advanced unresectable tumor with limited treatment options and a rather poor prognosis. Recently, atezolizumab plus bevacizumab was introduced as a new first-line combination therapy regimen for unresectable-HCC (u-HCC), but its use is restricted to patients with compensated liver function (ie, Child-Pugh [CP] class A liver function).

Initial results of screening program in Mongolia where burdening high gastric cancer

www.doi.org/10.52768/jjgastro/1136

Mongolia is the leading country by the incidence and mortality rate of gastric cancer. In 2022 national cancer screening program for upper gastrointestinal neoplasia was initiated therefore we conducted the multi-center study for determining the gastric cancer among Mongolian population.